Immunic Q4 2020 Earnings Report
Key Takeaways
Immunic reported its year-end 2020 financial results, highlighting positive data from clinical trials of IMU-838 and a bolstered balance sheet with $127.5 million in cash and cash equivalents.
Phase 3 program of IMU-838 in Relapsing-Remitting Multiple Sclerosis is expected to begin in the second half of 2021.
Reported positive top-line data from investigator-sponsored Phase 2 proof-of-concept clinical trial of IMU-838 in Primary Sclerosing Cholangitis.
Announced main analysis of Phase 2 CALVID-1 Trial of IMU-838 showing evidence of clinical activity in patients with moderate COVID-19.
Significantly bolstered balance sheet, raising approximately $144.4 Million of Cash During 2020.
Immunic
Immunic
Forward Guidance
Immunic is funded into the second half of 2022 and anticipates several clinical milestones.
Positive Outlook
- Phase 3 program of IMU-838 in RRMS expected to begin in the second half of 2021
- Anticipated clinical milestones include data from Cohort 2 sub-trial of IMU-838 in RRMS
- Formal end-of-phase 2 meeting requests to discuss the proposed phase 3 program with major regulatory authorities around the end of the first quarter of 2021
- Outcome of the end-of-phase 2 meetings are expected to be available in or about May 2021.
- Feasibility activities for a phase 3 program of IMU-838 in RRMS, including country and site selection, as well as other preparatory activities.